

its degradation, causes accumulation of serotonin. This is associated with agitation, psychosis and other forms of abnormal behavior. Chlorpromazine and Phe- nergan may produce their tranquilizing ef- fects by specifically antagonizing serotonin. (*Page, I. H.: Serotonin (5-Hydroxytrypta- mine); Last Four Years, Physiol. Rev. 38: 277 (April) 1958.*)

PITRESSIN SUBSTITUTE Realizing the serious coronary constriction that Pi- tressin may produce but still needing a hemostatic agent to facilitate uterine opera- tions such as myomectomies, the authors investigated vasopressin, isolated from hog pituitaries. When they injected a solution of 0.2 unit per milliliter into the operative site, they obtained blanching of the uterus for 15 to 20 minutes. Blood loss was remarkably reduced and there were no cardiac, circulatory or other significant complications. (*Dillon, T. F., and others: Vasopressin as Hemostatic in Gynecologic Surgery, Obst. & Gynec. 11: 363 (April) 1958.*)

PLACEBOS An attempt has been made to describe lesser known aspects of the "pharmacology" of placebos by describing the ways in which the clinical use of inert substances may lead to effects which are usually considered to be the exclusive prop- erty of active agents. One of the basic indices of pharmacologic activity is the time-effect relationship. Placebos can also show this behavior. A comparison is made between aspirin and a placebo. Although the mean score for the placebo relief was somewhat lower the difference was not statistically significant. Placebos may also show a "build-up" in effect, and there may be a "carry-over" after cessation of ther- apy. Another general characteristic of drugs is the inverse relationship of their efficacy to the severity of a given complaint. This relationship for placebos has also been apparent. This finding is somewhat at variance with the report of Beecher who found that patients studied early in the postoperative period are handled almost as well by placebo as by morphine, whereas later in the postoperative course morphine performs much better than the placebo. (*Iasagna, L., Laties, V. G., and Dohan,*

J. L.: Further Studies on "Pharmacology of Placebo Administration, J. Clin. Invest. 37: 533 (April) 1958.)

PREANESTHETIC MEDICATION Data obtained in a blind study of morphine, meperidine, alphaprodine, secobarbital and saline solution as preanesthetic medica- ments in 1,400 surgical patients showed that secobarbital led to a higher proportion of calm, carefree, yet alert patients than did the narcotics. Undesirable side effects were seen more often after preanesthetic narcotics than with secobarbital. There was little difference in the influence of the various drugs upon satisfactory induction of anesthesia with any given anesthetic agent. Preanesthetic drugs did not appear to influence maintenance of anesthesia, ex- cept that respiratory depression was more common if a preanesthetic narcotic had been given. Patients who received preop- erative narcotics remained narcotized longer after anesthesia than those who received secobarbital or saline, but they did not complain of pain as often nor appear as restless as the latter group. Of the drugs studied, dosages considered to be equipot- ent were: morphine, 5 mg.; meperidine, 50 mg.; alphaprodine (Nisentil), 30 mg.; secobarbital (Seconal), 75 mg. (*Eckel- hoff, J. E., and Helrich, M.: Study of Nar- cotics and Sedatives for Use in Prean- esthetic Medication, J. A. M. A. 167: 481 (May 24) 1958.*)

NALORPHINE The outstanding dif- ferences in the human pharmacology of nalorphine as compared with morphine are: (1) relative low potency of single doses of nalorphine in inducing sedation; (2) lesser degree of pupillary constriction, depression of temperature, depression of respiratory rate, and minute volume after single doses of normorphine; (3) marked accumulation of sedative effects of nalorphine during repeated administration, and (4) relatively slow onset and mildness of the abstinence syndrome after withdrawal of nalorphine. (*Fraser, H. F., and others: Human Phar- macology and Addiction Liability of Nalorphine, J. Pharmacol. & Exper. Therap. 122: 359 (March) 1958.*)

LEVALLORPHAN The addition of levallorphan to meperidine, in a 1:100